Filgotinib maleate is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. It effectively inhibits JAK1, JAK2, JAK3, and TYK2. It also inhibits HIV-1 driven gene transcription and reduces proliferation of HIV-1 infected cells. It can be used in the study of rheumatoid arthritis and inflammatory bowel disease.
- Inhibits differentiation of Th2 cells and Th1 cells.
- Produces dose-dependent bone damage protection.
- Prevents the development of inflammation in animal models of collagen-induced arthritis.
- Reduces inflammatory cell infiltration.
- Protects articular cartilage and bone.
- Reduces serum levels of inflammatory cytokines and chemokines.